NTLA
Intellia Therapeutics Inc

14,051
Mkt Cap
$1.11B
Volume
4.03M
52W High
$28.25
52W Low
$5.90
PE Ratio
-2.25
NTLA Fundamentals
Price
$9.61
Prev Close
$9.74
Open
$9.59
50D MA
$15.49
Beta
1.74
Avg. Volume
7.5M
EPS (Annual)
-$5.25
P/B
1.49
Rev/Employee
$143,615.39
Loading...
Loading...
News
all
press releases
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 7.1% - Should You Buy?
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 7.1% - What's Next...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Intellia Therapeutics, Inc. $NTLA Shares Sold by Orchard Capital Management LLC
Orchard Capital Management LLC cut its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 57.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm...
MarketBeat·7d ago
News Placeholder
Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?
Intellia advances in vivo pipeline with lonvo-z through its pivotal HAELO study, eyeing mid-2026 data and a potential 2026 filing to propel growth.
Zacks·8d ago
News Placeholder
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?
Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.
Zacks·9d ago
News Placeholder
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of "Hold" from Analysts
Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has earned an average rating of "Hold" from the twenty-four brokerages that are covering the company, MarketBeat reports. Three equities...
MarketBeat·9d ago
News Placeholder
Intellia Therapeutics (NASDAQ:NTLA) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen upgraded Intellia Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·13d ago
News Placeholder
NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?
Intellia sinks 67% in a month after a clinical hold on nex-z and mixed third-quarter results, raising questions about its pipeline outlook and near-term direction.
Zacks·15d ago
News Placeholder
Discovery Value Fund Sells 332,860 Shares of Intellia Therapeutics, Inc. $NTLA
Discovery Value Fund decreased its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 59.3% in the second quarter, according to its most recent filing with the Securities & Exchange...
MarketBeat·15d ago
News Placeholder
Top 3 Genomics Stocks to Consider for Your Portfolio
Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
Zacks·18d ago
News Placeholder
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.
Zacks·22d ago

Latest NTLA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.